NRC and Glysantis Join Forces to Test Innovative Nanomaterial
Partners evaluating nanoparticle NanoGlys(TM) as vaccine adjuvant and drug delivery vehicle
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 01/14/16 -- Guelph-based Glysantis Inc. and Canada''s "go-to" research and technology organization are investigating the potential of the NanoGlys™ nanoparticle for biomedical applications. The up-and-coming Canadian life science company is taking advantage of the National Research Council of Canada''s (NRC) expertise and preclinical models to study how NanoGlys™ could be used as a vaccine adjuvant, drug delivery vehicle, and medical imaging agent.
The first phase of testing will confirm the safety of NanoGlys™, as well as the nanoparticle''s ability to reach targeted biological sites and be cleared away thereafter. Future studies will explore if NanoGlys™ can successfully deliver chemotherapeutic agents directly to diseased cells or tissue, and confirm its therapeutic efficacy. The feasibility studies are of strategic importance in determining the most promising applications of the nanoparticle for further development.
Quick Facts
Quotes
"The development of new adjuvants and immunomodulators could have a major impact on the efficacy of many vaccines. The National Reseach Council is proud to participate in this innovative project with an up-and-coming Canadian life science company."
Dr. Roman Szumski, Vice-President of Life Sciences at the National Research Council of Canada
"The National Research Council''s outstanding capabilities and deep expertise in areas of interest to Glysantis are an excellent basis for our preclinical research and development programs. We are excited about this partnership for the development of our technology."
Dr. Thomas Engelhardt, President of Glysantis Inc.
Additional Links
-
-
Twitter:
Contacts:
Media Relations Team
National Research Council of Canada
1-855-282-1637 (toll-free, 24/7, in Canada only)
1-613-991-1431 (elsewhere in North America)
Dr Thomas Engelhardt, President
Glysantis Inc.
1-919-923-2159
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.01.2016 - 10:30 Uhr
Sprache: Deutsch
News-ID 1409006
Anzahl Zeichen: 3014
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
Government & Administration
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 151 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NRC and Glysantis Join Forces to Test Innovative Nanomaterial
"
steht unter der journalistisch-redaktionellen Verantwortung von
National Research Council Canada-NRC and Glysantis Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
